In the Journals

QLT initiates phase 2 trial of impaired dark adaptation treatment

QLT initiated a phase 2a proof-of-concept trial of QLT091001, a synthetic oral retinoid, in adult subjects with impaired dark adaptation, according to a press release.

Subjects in the randomized, multicenter, parallel-group, placebo-controlled study are 60 years of age or older with impaired dark adaptation, or impaired low-luminance low-contrast best corrected visual acuity, in at least one eye with no known ophthalmic pathologies to explain the condition other than early age-related macular degeneration, the release said.

Subjects will receive placebo or one of two doses of QLT091001 — 10 mg/m2 or 40 mg/m2 — once a week for 3 consecutive weeks with one additional dose the day after the third dose, according to the release.

The trial will evaluate the safety profile and effects of QLT091001 on impaired dark adaptation time, glare recovery time and impaired low-luminance low-contrast best corrected visual acuity.

QLT initiated a phase 2a proof-of-concept trial of QLT091001, a synthetic oral retinoid, in adult subjects with impaired dark adaptation, according to a press release.

Subjects in the randomized, multicenter, parallel-group, placebo-controlled study are 60 years of age or older with impaired dark adaptation, or impaired low-luminance low-contrast best corrected visual acuity, in at least one eye with no known ophthalmic pathologies to explain the condition other than early age-related macular degeneration, the release said.

Subjects will receive placebo or one of two doses of QLT091001 — 10 mg/m2 or 40 mg/m2 — once a week for 3 consecutive weeks with one additional dose the day after the third dose, according to the release.

The trial will evaluate the safety profile and effects of QLT091001 on impaired dark adaptation time, glare recovery time and impaired low-luminance low-contrast best corrected visual acuity.